Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Austria Germany Greece Italy The Netherlands
  • Study on Elranatamab for Patients with Multiple Myeloma Continuing from Previous Clinical Trials

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Spain
  • Study on [68Ga]Ga-PentixaFor PET Imaging for Better Risk and Disease Assessment in Patients with Multiple Myeloma

    Recruiting

    1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium The Netherlands
  • Study on Human Normal Immunoglobulin and Sodium Chloride to Prevent Infections in Patients with Chronic Lymphocytic Leukemia

    Recruiting

    3 1 1
    Bulgaria Croatia Hungary Poland Romania
  • Study Comparing Iberdomide and Lenalidomide for Maintenance Therapy After Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Austria Belgium Czechia Denmark Finland France +10
  • Reduced vs Standard Dose Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Phase II MRD‑Guided Study

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    Poland
  • A Study to Assess Safety and Efficacy of Surzetoclax Alone or with Etentamig in Adults with Relapsed or Refractory Multiple Myeloma

    Not yet recruiting

    1 1 1
    Investigated Diseases:
    Belgium Czechia France Germany Greece Italy +3
  • Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

    Not yet recruiting

    3 1 1 1
    Czechia Denmark France Germany Greece Italy +2
  • Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Germany
  • AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

    Not yet recruiting

    3 1 1 1
    France Germany Italy Norway Poland Spain